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Abstract
The wide-scale roll-out of artemisinin combination therapies (ACTs) for the treatment of malaria should be accompanied by
continued surveillance of their safety. Post-marketing pharmacovigilance (PV) relies on adverse event (AE) reporting by
clinicians, but as a large proportion of treatments are provided by non-clinicians in low-resource settings, the effectiveness of
such PV systems is limited. To facilitate reporting, AE forms should be easily completed; however, most are challenging for
lower-level health workers and non-clinicians to complete. Through participatory research, we sought to develop user-friendly
AE report forms to capture information on events associated with ACTs.
Following situation analysis, we undertook workshops with community medicine distributors and health workers in Jinja,
Uganda, to develop a reporting form based on experiences and needs of users, and communication and visual perception
principles. Participants gave feedback for revisions of subsequent versions. We then conducted 8 pretesting sessions with 77
potential end users to test and refine passive and active versions of the form.
The development process resulted in a form that included a pictorial storyboard to communicate the rationale for the
information needed and facilitate rapport between the reporter and the respondent, and a diary format to record the drug
administration and event details in chronological relation to each other. Successive rounds of pretesting used qualitative and
quantitative feedback to refine the form, with the final round showing over 80% of the form completed correctly by potential
end users.
We developed novel AE report forms that can be used by non-clinicians to capture pharmacovigilance data for anti-malarial
drugs. The participatory approach was effective for developing forms that are intuitive for reporters, and motivating for
respondents. The forms, or their key components, could be adapted for use in other low-literacy settings to improve quality
and quantity of drug safety reports as new medicines are scaled-up.
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Introduction
Since 2004, artemisinin combination therapies (ACTs) have
been scaled-up rapidly worldwide. ACTs have a good safety
profile in clinical trials and are among some of the most widely
used drugs in the world. However, programmatic safety data from
the ‘real world’, where drugs will be used repeatedly and often
presumptively at health centre and community level in high-
transmission settings, cannot be captured well by standard post-
marketing pharmacovigilance systems in endemic areas [1]. Post-
marketing pharmacovigilance is intended to build on safety data
obtained in clinical trials, aiming to collect sufficient quality data to
be able to identify rare, serious adverse events (AEs), and to obtain
more information on the nature and burden of known AEs in the
general population. Despite encouragement for inclusion of
pharmacovigilance activities in national malaria control plans
[2], implementation has been inconsistent, and pharmacovigilance
coverage remains low in many countries [3].
Improved pharmacovigilance requires more data of better
quality. However, reporting adverse events in programmatic
settings can be particularly challenging, and forms often require
individuals completing the forms to negotiate, translate and
interpret this complexity. Although a valid AE report requires only
four essential fields; patient, reporter, drug name and event
description [4]; more detailed information about the patient and
the event is required to conduct meaningful assessments and to
characterise emerging safety signals with reliability. This com-
plexity is likely to contribute to the low numbers of events reported
and the poor quality of reports.
Relatively little attention has been paid to the way information
is recorded on reporting forms. Most countries rely primarily on
spontaneous adverse drug reaction (ADR) reporting schemes
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similar to the UK’s Yellow Card scheme [5]. However, reporting
forms tend to be developed by those interpreting the forms, rather
than those collecting the data. They may also assume that the
patient’s history is captured elsewhere, as would be the case in a
controlled-trial setting. Such assumptions, embedded into the
design of reporting forms, limit their broader usability and
usefulness. Formal and informal health workers, commonly
involved in malaria treatment provision in sub-Saharan Africa,
may be unfamiliar with formal pathways for reporting, and the
complexity of AE forms may further deter them from reporting
[6]. Patients may not report due to fear of incrimination from
health workers and perception that some AEs are actually
indicators of drug efficacy, rather than side-effects, such as itching
with chloroquine [6–8]. Further complicating reporting of adverse
events following antimalarial treatment is the challenge of
distinguishing between symptoms of malaria and AEs [9,10].
Reporting forms that present the course of events clearly, with
minimal need for interpretation at the time of recording the event,
are therefore essential. Forms suitable for passive and active data
collection are also needed. Passive data collection forms are
required for spontaneous reporting, when patients present with
symptoms that are reported as an AE. Active data collection forms
are needed for clinical trials or cohort event monitoring, to
monitor all patients in the study population.
We developed new passive and active reporting forms to
document AEs following treatment with ACTs, aiming to produce
a format that targets issues most important to those involved in
reporting, to improve detection of adverse drug reactions and to
enhance collection of high quality information by lower-level
health workers involved in pharmacovigilance.
Methods
We used participatory methods to develop a new reporting
form. This approach engages the target audience in the problem
defining and solving process [11], in order to produce interven-
tions that are more likely to be taken up by end users.
Project site and team
This project is part of a larger study to collect safety data from
studies conducted by the ACT Consortium (www.actconsortium.
org) in seven countries. We carried out this work in Uganda, where
we were familiar with the pharmacovigilance system, and where
AE reporting in communities and at drug shops was ongoing,
supported by the Uganda Malaria Surveillance Project (UMSP).
Fieldwork took place in Budondo, a rural sub-county in Jinja
district. Final pretesting took place in Kampala. The field team
consisted of a pharmacist (ED), social scientists (CC and SI), a
social scientist/communication specialist (AH), two clinicians (SS
and CK), two local artists and a team of 5 social science assistants
who were trained for the pretesting activities (by AH) following
best practice methods [12–14].
Participants
We selected participants to represent those who would
potentially collect AE data. In Budondo, community medicine
distributors (CMDs), health workers from public health facilities,
and UMSP fieldworkers were selected. CMDs are literate
members of the community, without formal medical training,
who were elected to participate in Uganda’s home-based
management of fever (HBMF) programme. Many CMD partic-
ipants were also involved in the UMSP pharmacovigilance
programme and had experience reporting AEs. In Kampala,
members of the UMSP research team conducting pharmacov-
igilance activities and university graduates were recruited to
pretest the final versions of the reporting forms. Graduates were
selected to represent those likely to be recruited as non-clinical
field workers in research projects.
Conceptual framework
The process of AE report generation typically involves
transformation, or ‘concretisation,’ of an individual’s experience
into a report relevant for pharmacovigilance. First, the patient or
caregiver must decide whether their experience merits action
contingent upon their understanding of illness and disease, and the
perceived ease and outcomes of different actions, including
reporting the adverse experience as an event. Second, their
subjective illness and treatment experience must be translated into
what they consider to be medically recognized categories [7].
Third, the reporter must filter and concretise the experience
further into what they consider to be empirically verifiable
biomedical phenomena that can be written down and hold
meaning for those interpreting the report. Fourth, the reporter or a
third party must interpret the respondent’s experience, now
considered to be ‘data,’ and assign what they consider to be the
severity of the event, and causality between the event and
treatment received. In each of these stages, cultural expectations,
including from ethnomedical and biomedical paradigms, and
communicated by the reporter to the respondent, shape what is
considered relevant to report. The process is akin to that of the
transformation from illness to disease, from a subjective experience
to a physical and measurable phenomenon [15].
Project design
The project involved three phases: (1) Review of existing forms, (2)
form development, when intended end-users participated in
workshops to help design simple forms, and (3) pretesting, which
involved one observation phase with CMDs and a formal testing
phase with graduate fieldwork recruits and CMDs in Kampala
(Figure 1). The fieldwork activities overlapped with analysis, allowing
the team to plan the next steps. Analysis of interviews, discussions
and observations involved manually reviewing transcripts and
fieldnotes for main themes and concerns of participants, drawing
out those related to AE reporting. Quantitative analysis of pretesting
involved descriptive statistics using Excel.
Review of existing forms. To understand how current
pharmacovigilance reporting forms were being used in Uganda, we
undertook a review of three types of AE forms completed by different
health care providers: clinicians, drug-shop owners, and CMDs. The
first was the Ugandan National Drug Authority (NDA) form; the
others were developed by UMSP for use in pharmacovigilance
activities.We noted where problems occurred in previously completed
forms and then conducted a field visit to observe and discuss the use of
forms by a small convenience sample of health workers, CMDs and
drug shop workers active in local pharmacovigilance projects. We
discussed these findings with project staff responsible for interpreting
AE forms and entering data, to understand their perspectives on the
reporting system and ideas for improvements. We then reviewed the
forms in two focus group discussions with CMDs and then health
workers, in which participants were encouraged to discuss their
experiences with anti-malarial treatment and reporting of AEs with
existing forms and procedures.
Form development. In the form development phase, we
produced a draft form for passive reporting. We held two
participatory workshops, one with CMDs and one with health
workers. In the workshops participants were divided into small
groups and asked to draft a simple reporting form, basing the
layout on their own understanding of what was important to
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include. A local artist drafted and refined sketches at the request of
participants. The artist was briefed on principles for drawing
pictures that are understandable to low-literacy audiences [16].
Participants in the first workshop were then presented with ideas
originating from our evaluation of the challenges and opportunities
presented by the forms reviewed previously. Participants were
invited to consider whether to incorporate these ideas into their own
forms. We allowed time to develop trust that we wanted the
participants’ ideas and contributions in order to establish motivation
and commitment towards the development of a good quality form.
Facilitators moved between the working groups to encourage
participants to include essential data fields for pharmacovigilance
Figure 1. Overview of project design.
doi:10.1371/journal.pone.0032704.g001
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within the form. We asked groups to practice using their draft forms
in role plays, and to make relevant adaptations.
Following their workshop, CMDs were asked to take the latest
draft form home to practice recording AEs, and were invited to
attend a follow-up workshop to give feedback on the existing draft.
Pretesting. Prior to formal pre-testing, to evaluate how the
new reporting forms would work in practice, we asked the CMDs
and health workers to practice with the forms informally, using
friends and neighbours as informants, with real cases where
possible, alongside their existing data collection forms. They were
observed in the field (by SI), who monitored participants’ use of the
form, the time taken for completion and suggestions for
improvement. He later added his own suggestions, based on an
understanding of the context in which it was used. Participants were
invited to a final workshop following the trial period to provide
feedback of their experiences of completing the reporting form.
Following the informal testing of the form in the field, we
conducted formal pretesting in Kampala. Pretesting involved
testing each section of the form for comprehension (interpretation
of pictures, text and ideas), and for usability (correct completion of
the fields). First, we pretested an active reporting form, adapted
from the draft passive form, with university graduates acting as
potential field workers. We then applied relevant revisions to the
passive form and pretested this form with graduates and CMDs.
Pretesting involved a series of day-long sessions attended by
around 10 graduates or CMDs (‘users’) and facilitated by a trained
pretesting team. In each session, users were given an introduction to
pharmacovigilance and the purpose of the pretesting, before
participating in training in how to use the draft reporting form.
Each user then completed the form by interviewing a member of the
pretesting team acting as the patient or caregiver. In each round,
users tested the form in up to three pre-prepared clinical scenarios.
During the role play, the pretester observed how the user completed
the form and any problems that emerged. On completing the form
and ending the role play, the pretester asked the user for their
feedback and made notes on comprehension and use of the form.
Pretesting workshops were held in English, although for the passive
form pretesting with CMDs, members of the research team were
able to translate to the local language where necessary.
Reviews were undertaken after each pretesting session. A
quantitative analysis calculated the proportion of the entries on the
form that were ‘correct’ when compared with a pre-completed
version of the form. Comprehension was assessed by looking at those
sections of the form that were less well completed and addressing
misunderstandings about how to complete those sections. The forms
were updated based on feedback from participants at the end of each
day, and the pretesting cycle continued. We aimed to achieve 80–
90% understanding of the reporting form.
Ethics Statement
All participants were given information about the project and
were asked to give verbal consent to participate. Ethics approval
for this work was received from the Research Ethics Committees
of Uganda National Council of Science and Technology
(Reference number HS433), Makerere University (Reference
number 2008-037), London School of Hygiene and Tropical
Medicine (application 5241) and the Liverpool School of Tropical
Medicine (protocol 09.56).
Results
Review of existing forms
21 participants demonstrated, discussed and evaluated existing
pharmacovigilance tools with the project team. The review
revealed challenges completing all available AE forms. In many
completed forms, we observed inconsistency in detail about the
event and the patient, limiting the scope of AE assessment. The
key problems we identified with completion of the forms are
described in Supporting Information S1. In addition to challenges
specific to the format of forms, our analysis highlighted challenges
with the wider process of AE reporting. These included identifying
a case as relevant to report, eliciting relevant information from
patients, interpreting patient explanations, and recording infor-
mation on the reporting form.
Focus Group Discussion. Ten CMDs, all active in
pharmacovigilance, and nine health workers with a range of
experience and qualifications and no prior AE reporting
experience, participated in the two workshops with focus group
discussions to review existing forms, and then subsequently in the
form development workshops.
In their focus group discussion, the challenges of interpreting
and recording the patient’s story were described. CMDs revealed
specific logistical challenges of the existing forms:
‘We have to jump from the first column to the fourth column and then to
the sixth and back.’
‘Types of drug are difficult to record-some people don’t know what has
been taken.’
The CMDs described how patients presented information to
them in terms of the trajectory of the illness, including the timeline
of the symptoms and treatment, which were often described in
relation to other non-medical events.
‘This is what we have been complaining of. It [the form] doesn’t bring
out what we get from our clients. If you are telling someone a story and
use that form, they will not get what you are saying … We don’t move
with our forms – we move with small books where we write, then after
we come back and fill in.’
The need to capture more of the complexity around patient
narratives was identified by CMDs as central to a useful reporting
form.
Health workers reported that they generally believed side-effects
were already well known by the drug manufacturers who list them
on leaflets and packaging. Serious AEs were also identified, such as
optic atrophy and severe anaemia, but these were still conceptu-
alised as expected side-effects that needed treatment or advice.
Health workers and CMDs described challenges of motivating
patients to report information about AEs. CMDs identified
changes in community involvement over time: lack of feedback
from reporting of previous events had made them less likely to
report current events. Health workers reported that eliciting
accurate information from patients was challenging, particularly
regarding what medicines they had taken, especially herbs.
Although health workers reported probing for other drugs,
patients were reluctant to tell them because of ‘stigma’ and ‘fear’
because ‘they think we will react to them.’ A clear need was expressed
for education of both patients and health workers about the
reasons for, relevance and value of reporting.
Form development
We evaluated our review of existing forms in the light of
communication and visual perception principles and previous field
experience. We developed the idea of a diary format to represent
chronological events, and a pictorial strip to show and explain the
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purpose of reporting AEs, and the need for cooperation between the
respondent and reporter. Two series of pictures were developed by
the artist with guidance from the communication specialist; one for
adults and one for children, using line drawings. Figure 2 shows the
draft of the pictorial strip for reporting adverse events in children.
Documenting the patient’s story chronologically
In their original drafts of the form, CMDs followed formats they
were familiar with, writing a series of questions in columns.
However, in role-plays, participants identified that this style had
limitations in capturing the necessary data, especially regarding
the relationship between dosage timing and symptoms of emerging
events. When the diary format was introduced, the participants
responded positively as it enabled them to ‘bring out the whole story.’
In the second workshop, the health workers built on the diary
format idea, suggesting additional fields for inclusion including
specifics of patient information.
Participants decided that the core of the patient story should be
reported in the diary, helping the patient to follow what they are
recording, and prompting the patient to think chronologically.
Participants also recognised the need for additional fields to
document further details about the reported information and the
diary was coupled with a more traditional column-based section
for follow-on questions.
Communicating the purpose of the form. The importance
of cooperation between the person completing the form and the
respondent was emphasized. Presented with the draft pictorial
strips, CMDs and health workers discussed and tested their
contents and use, and suggested revisions to the pictures. They also
suggested adding text to remind the user to show and explain the
pictures to the patient. The artist undertook several revisions of the
pictorial strips before arriving at the final version for pretesting.
Review of forms after practice. Following practice with the
draft form at home, the CMDs shared their experiences and made
suggestions for improvements. The diary format was well
accepted, as was the storyboard, which appeared to achieve its
objectives of improving patient motivation to report and
cooperation with the reporter:
‘People can understand this picture… As I was filling the form they
were experiencing what I was doing’
‘From the pictures I have seen that the CMD must be humble and
listening and you show the information, what you write, what he’s
telling you, you must be aware. And it says why you are visiting, why it
is needed to report.’
Generally, forms were completed as intended, although there
was some confusion over where to record data on the diary, and
the wording of some structured questions. Revisions were made,
and an example on a template form was created to help reporters
to remember how to complete the diary section.
Pretesting
Practice and observation in the field. Over two weeks, 13
CMDs and one health worker were observed completing the form.
Overall, the concepts appeared to be well understood; however,
the diary format and tables required explanation to the respondent
and further explanation to reporters. The language used in the
form (English) was not used in the interaction between the reporter
and the respondent. Adjustments were made to the draft form,
with the intention to translate final versions of the form for local
use where necessary.
The pictorial strips was sometimes overlooked, particularly in
literate patients,
‘The pictures are not needed if the person is learned; they understand
why we are here’.
However, both respondents and CMDs were keen that the
pictures remained, and interpreted them in the intended way
whenever questioned. When the observer asked the CMD to begin
with the storyboard when interviewing a respondent who
appeared literate, the session was a more interactive engagement
between interviewer and respondent, providing good reason for
the pictorial strips to be retained with minor adaptations.
The passive draft form was adapted for active data collection.
The two forms were similar except on the active form additional
space for recording baseline information including prescription
and laboratory data was included.
Formal pretesting in Kampala. Formal pretesting of the
forms was carried out over 8 days in Kampala. Five rounds of
pretesting were completed for the active reporting form, with 50
Figure 2. Pictorial strip first draft, demonstrating reporting of a child’s adverse event.
doi:10.1371/journal.pone.0032704.g002
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university graduates, using three different clinical scenarios
(detailed in Supporting Information S2). The median score for
the form was high, with the greatest challenges found in the diary
section. As the pretesting progressed, changes included improving
training in the use of the diary, revising the question wording, and
changing the storyboard picture from rash to vomiting which was
considered a better choice for patient understanding (Figure 3).
The change of picture was specific to active forms: users felt the
vomiting image encouraged them to report any symptom, rather
than symptoms traditionally associated with drug reactions, such
as rash. The median total score improved across the different
sections of the reporting form from 79% in the first round to 92%
in the final round. Scores are presented in Table 1.
Three rounds of pretesting of the passive reporting form were
completed with 9 graduates and 17 CMD users, using three
different clinical scenarios (Supporting Information S3). Users
completed these passive forms well, with high median scores for
both graduates and CMDs (Table 2). We made minor revisions to
the form in each round of pretesting, for example changing
‘antimalarial’ to recognised local brand names, and providing
specific training on parts of the form, such as the use of arrows to
indicate the duration of an event. Overall, we received positive
feedback on the use of the pictures and users stated that the form
could be used easily with practice. The final draft of the passive AE
reporting form is shown in Figure 4 and Figure 5. Completed
versions of the active and passive forms can be found in
Supporting Information S4 and Supporting Information S5.
Discussion
Expanding pharmacovigilance programmes beyond the formal
public health sector presents an opportunity to improve the
coverage of collection of drug safety data. Using a participatory
research approach, we developed and pretested user-friendly AE
reporting forms designed to be used by lower-level health workers
and non-clinicians, and achieved high reporting accuracy: over
80% of the sections were completed correctly in role-play
scenarios.
We found that existing forms were often poorly completed, even
by clinicians, in line with previous studies [3,6]. A major problem
with existing forms was their ‘black boxing’ of the processes of
translating and transcribing experiences to recorded reports: the
realities of patients’ illness events and the elicitation and
documentation processes did not fit well onto the reporting forms
that required pre-processed ‘data.’ Consistent with findings
elsewhere [7,8,15], participants described difficulties for patients
to report ‘relevant’ information, for reporters to filter this into
‘relevant’ data and for those receiving reports to attribute causality
Figure 3. Pictorial strip after workshops and pretesting for active reporting.
doi:10.1371/journal.pone.0032704.g003
Table 1. Use of active reporting form over five pretesting and
revision sessions.
Day
No of
participants
Role-play
scenario
Median diary
score (%)
Median total
Score (%)
1 9 A 61 79
2 10 A 70 75
6 B 66 58
3 10 A 68 85
4 11 B 86 86
3 C 96 98
5 8 A 77 92
9 B 75 87
8 C 77 89
doi:10.1371/journal.pone.0032704.t001
Table 2. Use of passive reporting form over three pretesting
and revision sessions.
Day
Type of
Participants
Number of
participants Scenario
Median Total
Score (%)
1 Graduates 8 A 85
3 B 71
9 C 77
2 CMDs 6 C 80
3 CMDs 6 A 86
6 B 81
doi:10.1371/journal.pone.0032704.t002
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in a relative vacuum of information. The design of our reporting
form took into account the difficulty of establishing relevance for
data reported and attempted to tackle this in several ways. For the
patient, the storyboard helps to set the scene for reporting and the
importance of establishing a partnership with the reporter. The
pictures show an equal rather than hierarchical relationship
between the patient and the reporter by showing them both
looking at the form and sharing information, known to be
important if information is to be shared freely [17]. This reflects
that the diary is intended to be completed by the reporter and
respondent together, to reduce the power differential assumed in
paternalistic health worker-patient relationships and promote
equal responsibility, trust and consensus in the decision [18], in
this case what to record on the form. For the reporter, the aim of
the form was shifted from documentation of an adverse drug
reaction to documentation of an illness episode, removing
responsibility for establishing causality. The design of the form
helps to do this by prompting for all symptoms and medical events
over the course of the illness, including pre-existing symptom and
medications, and the importance was reinforced in the prepara-
tory training for reporters. For the interpreter, far greater
information is available to inform causality assessment, particularly
regarding the chronology of events. Establishing clear chronology
also assists in differentiating pre-existing symptoms from those
developing after the suspected drug is taken and establishing if the
reported symptoms resolve on discontinuation of the medicine or
recur following recommencement of the medicine.
The participatory approach used in this research had a
significant impact on the format and content of the reporting
form developed. Participants influenced the design of pictures and
content for fields, and continuous rounds of testing enabled us to
identify important changes that enabled improved understanding
and completion of the forms. This follows other similar activities
that have developed successful community relevant strategies for
malaria and for onchocerciasis in Africa [16,19,20].
Our results suggest that non-clinicians are able to record good
quality drug safety data and could make important contributions
to pharmacovigilance programmes. This challenges current WHO
guidance that is cautious in its recommendation, ‘because of their
varying degrees of literacy [they] cannot act as reporters, but
should play an important role in referring patients to health
facilities to report reactions’ [21]. The approach we have taken,
asking the reporter to record all symptom and drug events on the
form, leaving interpretation of causality to those receiving the
data, could address these concerns, particularly the observation
that AE reports are ‘the product of the experience and diagnostic
logic of the reporter’ [22] . The development of these forms also
supports the recommendation from the WHO-MMV pharma-
covigilance consultation for the Affordable Medicines Facility -
malaria that simplified forms should be created for community
health workers and medicines vendors [23]. The use of low-
educated but trained workers to collect such information could
provide a middle-ground between clinician reports and direct
reports from patients and parents [24–26]. The collaboration with
Figure 4. Final draft of passive reporting form for adult patient (Page 1).
doi:10.1371/journal.pone.0032704.g004
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health personnel at such levels is also important to strengthen
sustainability, as lower-level personnel tend to be more stable in
the community.
There are limitations to our approach. Pharmacovigilance
programmes are complex and success relies on many factors
beyond reporting forms [27]. Further evidence is needed to
support the integration of community health workers in pharma-
covigilance activities at scale in routine programmes, especially in
relation to the meaning this role accords and sustainability of
motivation for volunteers in communities [28], as well as the need
for and cost of training and supervision for such programmes
[29,30]. User-friendly reporting forms with evidence of usability
by lower-level health workers and non-clinicians therefore
addresses just one gap for implementation.
The current design of the form has a short diary period, with the
focus on immediate and short time to onset events. Recall is usually
better over this short time period [31], although it would be useful to
assess whether chronology of events is accurately recalled and
captured with this form. Capture of delayed onset events might be
facilitated by an extension of the diary to a period of weeks, and
space for detailing narratives, but recall issues for respondents and
the level of literacy and pharmacovigilance expertise required by
reporters to unpick increasing numbers of confounding factors
means that such cases are best reserved for active follow-up by
specialised health workers. Due to practical restrictions in the
number of fields, the forms do not capture data on resolved
symptoms or completedmedicines prior to the illness episode, which
could limit interpretation of data. In addition, support would be
needed for these forms to be used effectively, particularly training of
reporters in completion of the diary component, and for the
principles behind the storyboard. Scale-up of the form would first
require its evaluation under different conditions. The form reported
here is demonstrated in our particular project population, has a
focus on malaria and artemether-lumefantrine, and used pretesting
scenarios that may not reflect the complexity of real life situations.
Evaluation of the forms in other settings, under routine reporting
conditions, and in comparison with existing forms would provide a
degree of generalisability and validity for antimalarial-specific
pharmacovigilance. Adaptation of the form, or its central
components of the storyboard and diary concept, with encourage-
ment of the reporter to ‘tell the patient’s story’, could be tested for
drugs to treat other diseases.
Conclusions
We took a participatory approach to create novel and effective
reporting forms for collecting much needed pharmacovigilance
data in resource-limited settings. The forms have been developed
and tested with a focus on antimalarials, in test scenarios in
Uganda, with planned field evaluations in programmatic settings.
The forms or their components could be adapted and tested for
other medicines, to encourage a unified patient-focussed approach
to pharmacovigilance reporting.
Figure 5. Final draft of passive reporting form for adult patient (Page 2).
doi:10.1371/journal.pone.0032704.g005
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Supporting Information
Supporting Information S1 Problems identified in re-
view of existing forms by end-users, experts and the
project team.
(PDF)
Supporting Information S2 Active pretesting scenarios.
(PDF)
Supporting Information S3 Passive pretesting scenarios.
(PDF)
Supporting Information S4 Completed active reporting
form.
(TIF)
Supporting Information S5 Completed passive reporting
form.
(TIF)
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